Arenaria – Talk Bio

Royalty Market Accelerates with XOMA Biotech Acquisitions and OrbiMed’s Major Fundraise

1 month ago talkbio0Tagged Arenaria, Biological Factors, Biological Science Disciplines, biopharma financing, Conditional, HilleVax, Investments, LAVA, M&A, mezigitamab, OrbiMed, royalty acquisition, XOMA Royalty

royalty acquisition; XOMA Royalty; biotech M&A; OrbiMed; biopharma financing; mezigitamab; Turnstone Biologics; HilleVax; LAVA Therapeutics; contingent value rights; life sciences investment

Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints

7 months ago talkbio0Tagged Arenaria, Biological Factors, clinical program, Discontinuation (procedure), Financial cost, Industry, Lymphocytes, Tumor-Infiltrating, Manufacturing, strategic alternatives, TIDAL-01

Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges

Turnstone Biologics Undergoes Strategic Restructuring with Layoffs and Leadership Changes

11 months ago talkbio0Tagged Arenaria, Biological Factors, Changing, Industry, Leadership, restructuring, strategic

Turnstone Biologics, layoffs, leadership changes, strategic restructuring, biotech industry